TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.81
+1.12 (+2.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close45.69
Open46.30
Bid0.00 x 1000
Ask46.73 x 1400
Day's Range45.38 - 47.30
52 Week Range24.21 - 67.54
Volume200,613
Avg. Volume395,142
Market Cap1.682B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    Press Releases
    • ACCESSWIRE

      Turning Point Therapeutics, Inc. to Host Earnings Call

      NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Turning Point Therapeutics, Inc. (NASDQ:TPTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020 ...

    • GlobeNewswire

      TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS

      Registrational Phase 2 TRIDENT-1 Study Continues Site Activation and Patient Enrollment Preclinical Data Highlighting Repotrectinib Combinations and Additional Data for TPX-0131.

    • GlobeNewswire

      Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and 2019 financial results following the close of U.S. financial markets on Mar. 18 and host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

    • GlobeNewswire

      Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and chief scientific officer effective March 2. Dr. Reich has over 25 years of pharmaceutical and biotech experience developing more than 20 drug candidates, including the approved drugs Viracept® for HIV and the tyrosine kinase inhibitor Inlyta® for the treatment of kidney cancer. Dr. Reich was most recently senior vice president of research and co-founder of eFFECTOR Therapeutics where he led discovery of three first-in-class small-molecule inhibitors, of MNK (tomivosertib), eIF4A (zotatifin), and eukaryotic initiation factor 4E (eIF4E).

    • GlobeNewswire

      Turning Point Therapeutics to Participate in Upcoming Investor Conferences

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Feb. 27 in New York and the Cowen 40th Annual Healthcare Conference on March 2 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

    • GlobeNewswire

      Turning Point Therapeutics to Participate in Guggenheim Oncology Day

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Guggenheim Healthcare Talks Oncology Day in New York on Feb. 13. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

    • GlobeNewswire

      Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of pharmaceutical and biotech oncology experience, including as the former president of Pfizer oncology where he led its global oncology franchise. “Garry brings deep expertise in oncology commercial strategy to the board at an important time for the company as we prepare for the potential commercialization of our lead asset,” said Dr. Sheila Gujrathi, chair of the Turning Point Therapeutics board.

    • GlobeNewswire

      Turning Point Therapeutics Announces Program Updates and Milestones for 2020

      Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site.

    • GlobeNewswire

      Turning Point Therapeutics Announces Management Transition

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that Dr. Jean Cui will step down as the company’s chief scientific officer for family reasons on Jan. 31. Dr. Cui will serve as a consultant and support the company during a transition period until June 30, 2020. “We are so grateful to Jean for all she has done as co-founder of the company, and we respect her decision to now prioritize her family’s needs,” said Dr. Athena Countouriotis, president and chief executive officer.

    • GlobeNewswire

      Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs. In this role, Ms. Yeganegi will lead the global product development team responsible for Turning Point Therapeutics’ lead drug candidate, repotrectinib, and as head of Medical Affairs will support the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies.

    • GlobeNewswire

      Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the 38th annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2020. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

    • GlobeNewswire

      Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

      SAN DIEGO, Nov. 12, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

    • GlobeNewswire

      Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

      SAN DIEGO, Nov. 11, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

    • GlobeNewswire

      Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

      Registrational Phase 2 Study of Repotrectinib Ongoing  Phase 1/2 Clinical Studies of RET/SRC Inhibitor TPX-0046 and Repotrectinib in Pediatric Patients On Track to Initiate in.

    • GlobeNewswire

      Turning Point Therapeutics to Host Third Quarter 2019 Conference Call

      SAN DIEGO, Oct. 21, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report.

    • GlobeNewswire

      Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

      SAN DIEGO, Sept. 30, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

    • GlobeNewswire

      Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its public offering of 4,500,000 shares of common stock at a price to the public of $45.00 per share. The gross proceeds to the company from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $202.5 million.  In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. Goldman Sachs & Co. LLC and SVB Leerink are acting as joint book-running managers for the offering.

    • GlobeNewswire

      Turning Point Therapeutics Announces Proposed Public Offering of Common Stock

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced today it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 4,500,000 shares of common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined.

    • GlobeNewswire

      Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor

      In TKI-naïve ROS1+ NSCLC Patients, Overall Response Rate by Blinded Review Improved to 91 Percent; Median Duration of Response Not Yet Mature with 20.1 months of Median.

    • GlobeNewswire

      Turning Point Therapeutics Participate in Upcoming Investor Conferences

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in the 2019 Wells Fargo Healthcare Conference and Citi’s 14th Annual Biotech Conference on Sept. 4-5 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

    • GlobeNewswire

      Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results

      FDA Accepts Repotrectinib Recommended Phase 2 Dose Regimen for Registrational TRIDENT-1 Study Two Abstracts Selected for Presentation at the European Society for Medical.

    • GlobeNewswire

      Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the 39th Annual Canaccord Genuity Growth Conference on Aug. 8 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

    • GlobeNewswire

      Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1 clinical study of patients with advanced solid tumors harboring genetic alterations in MET. “We believe the precision therapies we are designing and developing have potential to assist many patients with oncogenic driven cancers, making the start of this new clinical study an important step toward that goal,” said Athena Countouriotis, M.D, chief executive officer of Turning Point Therapeutics.

    • GlobeNewswire

      Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer

      Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today named Yi Larson as executive vice president and chief financial officer, effective Aug. 26. Ms. Larson joins the company from Goldman Sachs & Co. where she worked for more than 12 years and most recently served as managing director of Healthcare Investment Banking. “Yi brings an important new dimension to our growing team from her experience advising biotechnology companies through more than $100 billion in financing and strategic transactions,” said Athena Countouriotis, M.D, president and chief executive officer.